Parenchymsparende Operationen oder anatomische Resektionen bei Lebermetastasen des kolorektalen Karzinoms?

Zusammenfassung

Darmkrebs ist eine der häufigsten Todesursachen in der westlichen Welt. Die Hälfte der Patienten entwickelt kolorektale Lebermetastasen (CRLM), dabei weisen weniger als 30% der Patienten zum Zeitpunkt der Diagnose eine chirurgisch resektable Metastasierung auf. Im Falle einer Resektabilität bietet die klassische anatomische (Major-)Hepatektomie eine hohe R0-Resektionsrate, allerdings bei gleichzeitig erhöhter Morbidität und Mortalität. In den letzten 2 Jahrzehnten wurden die potenziellen Vorteile der parenchymsparenden Hepatektomie (PSH) in Bezug auf die onkologischen Gesamtergebnisse, das Überleben und die Re-Resektion im Falle eines Rezidivs („Salvageability“) nachgewiesen. Der Beitrag fasst die aktuellen Erkenntnisse zur PSH als chirurgische Therapieoption zusammen und diskutiert den aktuellen „state of the art“ in verschiedenen Szenarien.

Abstract

Colorectal cancer is one of the leading causes of death in the Western world. Half of the patients develop colorectal liver metastases (CRLM), while only less than 30% of the patients have surgically resectable metastasis at the time of diagnosis. In case of resectability, classical anatomical (major) hepatectomy offers a high R0 resection rate, but with simultaneously increased perioperative morbidity and mortality. Over the past two decades, the potential benefits of parenchyma-sparing hepatectomy (PSH) for overall oncological outcomes, survival, and re-resection in case of recurrence (“salvageability”) have been demonstrated. This article summarizes the current evidence on PSH as a surgical treatment option, and discusses the current “state of the art” in different therapy scenarios.

Schlüsselwörter

Darmkrebs - kolorektales Karzinom - Leberchirurgie - Lebermetastase - Leberresektion - Operationsstrategie

Keywords

colorectal carcinoma - liver metastasis - liver resection - operation strategy - parenchyma sparing

Publication History

Received: 15 February 2022

Accepted after revision: 03 May 2022

Article published online:
28 June 2022

• Literatur

• 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 DOI: 10.3322/caac.21492. (PMID: 30207593)
• 2 Jones RP, Kokudo N, Folprecht G. et al. Colorectal Liver Metastases: A Critical Review of State of the Art. Liver Cancer 2016; 6: 66-71 DOI: 10.1159/000449348. (PMID: 27995090)
• 3 Margonis GA, Buettner S, Andreatos N. et al. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases. Ann Surg 2017; 266: 641-649 DOI: 10.1097/SLA.0000000000002367. (PMID: 28657938)
• 4 Scheele J, Stang R, Altendorf-Hofmann A. et al. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71 DOI: 10.1007/BF00316981. (PMID: 7740812)
• 5 Folprecht G, Gruenberger T, Bechstein WO. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47 DOI: 10.1016/S1470-2045(09)70330-4. (PMID: 19942479)
• 6 Stintzing S, Miller-Phillips L, Modest DP. et al. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Eur J Cancer 2017; 79: 50-60 DOI: 10.1016/j.ejca.2017.03.023. (PMID: 28463756)
• 7 Brouquet A, Abdalla EK, Kopetz S. et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29: 1083-1090 DOI: 10.1200/JCO.2010.32.6132. (PMID: 21263087)
• 8 Wicherts DA, de Haas RJ, Salloum C. et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg 2013; 100: 808-818 DOI: 10.1002/bjs.9088. (PMID: 23494765)
• 9 Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008; 13: 51-64 DOI: 10.1634/theoncologist.2007-0142. (PMID: 18245012)
• 10 de Ridder JAM, van der Stok EP, Mekenkamp LJ. et al. Management of liver metastases in colorectal cancer patients: A retrospective case-control study of systemic therapy versus liver resection. Eur J Cancer 2016; 59: 13-21 DOI: 10.1016/j.ejca.2016.02.003. (PMID: 26994469)
• 11 Kopetz S, Chang GJ, Overman MJ. et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683 DOI: 10.1200/JCO.2008.20.5278. (PMID: 19470929)
• 12 Lintoiu-Ursut B, Tulin A, Constantinoiu S. Recurrence after hepatic resection in colorectal cancer liver metastasis – Review article. J Med Life 2015; 8(Spec Issue): 12-14 (PMID: 26361505)
• 13 Adson MA, Van Heerden JA. Major hepatic resections for metastatic colorectal cancer. Ann Surg 1980; 191: 576-583 DOI: 10.1097/00000658-198005000-00009. (PMID: 7369821)
• 14 Matsumura M, Mise Y, Saiura A. et al. Parenchymal-Sparing Hepatectomy Does Not Increase Intrahepatic Recurrence in Patients with Advanced Colorectal Liver Metastases. Ann Surg Oncol 2016; 23: 3718-3726 DOI: 10.1245/s10434-016-5278-0. (PMID: 27207097)
• 15 Mise Y, Aloia TA, Brudvik KW. et al. Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival. Ann Surg 2016; 263: 146-152 DOI: 10.1097/SLA.0000000000001194. (PMID: 25775068)
• 16 Aghayan DL, Kazaryan AM, Dagenborg VJ. et al. Long-Term Oncologic Outcomes After Laparoscopic Versus Open Resection for Colorectal Liver Metastases : A Randomized Trial. Ann Intern Med 2021; 174: 175-182 DOI: 10.7326/M20-4011. (PMID: 33197213)
• 17 Hamady ZZ, Lodge JP, Welsh FK. et al. One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Ann Surg 2014; 259: 543-548 DOI: 10.1097/SLA.0b013e3182902b6e. (PMID: 23732261)
• 18 Andreou A, Aloia TA, Brouquet A. et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 2013; 257: 1079-1088 DOI: 10.1097/SLA.0b013e318283a4d1. (PMID: 23426338)
• 19 Alvarez FA, Sanchez Claria R, Oggero S. et al. Parenchymal-sparing liver surgery in patients with colorectal carcinoma liver metastases. World J Gastrointest Surg 2016; 8: 407-423 DOI: 10.4240/wjgs.v8.i6.407. (PMID: 27358673)
• 20 Kokudo N, Tada K, Seki M. et al. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 2001; 181: 153-159 DOI: 10.1016/s0002-9610(00)00560-2. (PMID: 11425058)
• 21 Funamizu N, Ozaki T, Mishima K. et al. Evaluation of accuracy of laparoscopic liver mono-segmentectomy using the Glissonian approach with indocyanine green fluorescence negative staining by comparing estimated and actual resection volumes: A single-center retrospective cohort study. J Hepatobiliary Pancreat Sci 2021; 28: 1060-1068 DOI: 10.1002/jhbp.924. (PMID: 33638899)
• 22 Stavrou GA, Stang A, Raptis DA. et al. Intraoperative (Contrast-Enhanced) Ultrasound Has the Highest Diagnostic Accuracy of Any Imaging Modality in Resection of Colorectal Liver Metastases. J Gastrointest Surg 2021; 25: 3160-3169 DOI: 10.1007/s11605-021-04925-2. (PMID: 34159555)
• 23 Majlesara A, Golriz M, Hafezi M. et al. Indocyanine green fluorescence imaging in hepatobiliary surgery. Photodiagnosis Photodyn Ther 2017; 17: 208-215 DOI: 10.1016/j.pdpdt.2016.12.005. (PMID: 28017834)
• 24 Ignatavicius P, Oberkofler CE, Chapman WC. et al. Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons: A Throw of the Dice?. Ann Surg 2020; 272: 715-722 DOI: 10.1097/SLA.0000000000004331. (PMID: 32833764)
• 25 Kooby DA, Stockman J, Ben-Porat L. et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003; 237: 860-869 DOI: 10.1097/01.SLA.0000072371.95588.DA. (PMID: 12796583)
• 26 Moris D, Ronnekleiv-Kelly S, Rahnemai-Azar AA. et al. Parenchymal-Sparing Versus Anatomic Liver Resection for Colorectal Liver Metastases: a Systematic Review. J Gastrointest Surg 2017; 21: 1076-1085 DOI: 10.1007/s11605-017-3397-y. (PMID: 28364212)
• 27 Deng G, Li H, Jia GQ. et al. Parenchymal-sparing versus extended hepatectomy for colorectal liver metastases: A systematic review and meta-analysis. Cancer Med 2019; 8: 6165-6175 DOI: 10.1002/cam4.2515. (PMID: 31464101)
• 28 Pawlik TM, Scoggins CR, Zorzi D. et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241: 715-724 DOI: 10.1097/01.sla.0000160703.75808.7d. (PMID: 15849507)
• 29 Adam R, Delvart V, Pascal G. et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657
• 30 Gold JS, Are C, Kornprat P. et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg 2008; 247: 109-117 DOI: 10.1097/SLA.0b013e3181557e47. (PMID: 18156930)
• 31 Søreide K. Time to halt perioperative chemotherapy for resectable colorectal liver metastasis?. Br J Surg 2022; 109: 242-243 DOI: 10.1093/bjs/znab425. (PMID: 34875032)
• 32 Isoniemi H, Uutela A, Nordin A. et al. Centralized repeated resectability assessment of patients with colorectal liver metastases during first-line treatment: prospective study. Br J Surg 2021; 108: 817-825 DOI: 10.1093/bjs/znaa145. (PMID: 33749772)
• 33 Imai K, Allard MA, Castro Benitez C. et al. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br J Surg 2017; 104: 570-579 DOI: 10.1002/bjs.10447. (PMID: 28112813)
• 34 Yamashita S, Chun YS, Kopetz SE. et al. Biomarkers in colorectal liver metastases. Br J Surg 2018; 105: 618-627 DOI: 10.1002/bjs.10834. (PMID: 29579319)
• 35 Kanani A, Veen T, Søreide K. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Br J Surg 2021; 108: 1417-1425 DOI: 10.1093/bjs/znab342. (PMID: 34694371)
• 36 Hallet J, Sa Cunha A, Adam R. et al. Factors influencing recurrence following initial hepatectomy for colorectal liver metastases. Br J Surg 2016; 103: 1366-1376 DOI: 10.1002/bjs.10191. (PMID: 27306949)
• 37 Nordlinger B, Sorbye H, Glimelius B. et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016 DOI: 10.1016/S0140-6736(08)60455-9. (PMID: 18358928)
• 38 Primrose J, Falk S, Finch-Jones M. et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014; 15: 601-611 DOI: 10.1016/S1470-2045(14)70105-6. (PMID: 24717919)
• 39 Bosma NA, Keehn AR, Lee-Ying R. et al. Efficacy of perioperative chemotherapy in resected colorectal liver metastasis: A systematic review and meta-analysis. Eur J Surg Oncol 2021; 47: 3113-3122 DOI: 10.1016/j.ejso.2021.07.024. (PMID: 34420823)
• 40 Kanemitsu Y, Shimizu Y, Mizusawa J. et al. Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial. J Clin Oncol 2021; 39: 3789-3799 DOI: 10.1200/JCO.21.01032. (PMID: 34520230)
• 41 Stavrou GA, Ghamarnejad O, Oldhafer KJ. Why are too few patients with colorectal liver metastases submitted to resection?. Chirurg 2021; 92: 736-741 DOI: 10.1007/s00104-021-01363-3. (PMID: 33599805)
• 42 Donati M, Stavrou GA, Stang A. et al. ‘Liver-first’ approach for metastatic colorectal cancer. Future Oncol 2015; 11: 1233-1243 DOI: 10.2217/fon.14.316. (PMID: 25832880)
• 43 Buell JF, Cherqui D, Geller DA. et al. The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg 2009; 250: 825-830 DOI: 10.1097/sla.0b013e3181b3b2d8. (PMID: 19916210)
• 44 Schiffman SC, Kim KH, Tsung A. et al. Laparoscopic versus open liver resection for metastatic colorectal cancer: a metaanalysis of 610 patients. Surgery 2015; 157: 211-222 DOI: 10.1016/j.surg.2014.08.036. (PMID: 25282529)
• 45 Morise Z. Status and perspective of laparoscopic repeat liver resection. World J Hepatol 2018; 10: 479-484 DOI: 10.4254/wjh.v10.i7.479. (PMID: 30079134)
• 46 Scuderi V, Barkhatov L, Montalti R. et al. Outcome after laparoscopic and open resections of posterosuperior segments of the liver. Br J Surg 2017; 104: 751-759 DOI: 10.1002/bjs.10489. (PMID: 28194774)
• 47 Fretland ÅA, Dagenborg VJ, Bjørnelv GMW. et al. Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial. Ann Surg 2018; 267: 199-207 DOI: 10.1097/SLA.0000000000002353. (PMID: 28657937)
• 48 Inoue Y, Ishii M, Tashiro K. et al. Parenchyma-Sparing Hepatectomy or Major Hepatectomy for Colorectal Liver Metastases?. Am Surg 2018; 84: e181-e184 (PMID: 30219131)
• 49 Spelt L, Ansari D, Swanling M. et al. Parenchyma-sparing hepatectomy (PSH) versus non-PSH for bilobar liver metastases of colorectal cancer. Ann Gastroenterol 2018; 31: 115-120 DOI: 10.20524/aog.2017.0205. (PMID: 29333076)
• 50 Hosokawa I, Allard MA, Mirza DF. et al. Outcomes of parenchyma-preserving hepatectomy and right hepatectomy for solitary small colorectal liver metastasis: A LiverMetSurvey study. Surgery 2017; 162: 223-232 DOI: 10.1016/j.surg.2017.02.012. (PMID: 28434557)
• 51 Matsuki R, Mise Y, Saiura A. et al. Parenchymal-sparing hepatectomy for deep-placed colorectal liver metastases. Surgery 2016; 160: 1256-1263 DOI: 10.1016/j.surg.2016.06.041. (PMID: 27521044)
• 52 Lalmahomed ZS, Ayez N, van der Pool AE. et al. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome?. World J Surg 2011; 35: 656-661
• 53 Guzzetti E, Pulitanò C, Catena M. et al. Impact of type of liver resection on the outcome of colorectal liver metastases: a case-matched analysis. J Surg Oncol 2008; 97: 503-507 DOI: 10.1002/jso.20979. (PMID: 18425789)
• 54 Finch RJ, Malik HZ, Hamady ZZ. et al. Effect of type of resection on outcome of hepatic resection for colorectal metastases. Br J Surg 2007; 94: 1242-1248 DOI: 10.1002/bjs.5640. (PMID: 17657718)
• 55 Zorzi D, Mullen JT, Abdalla EK. et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 2006; 10: 86-94 DOI: 10.1016/j.gassur.2005.07.022. (PMID: 16368496)